. 2014 Jul-Aug;49(4):373-80.

doi: 10.1093/alcalc/agu021. Epub 2014 May 9.

Alcoholic liver disease: a synopsis of the Charles Lieber's Memorial Symposia 2009-2012

Manuela G Neuman¹, Lawrence Cohen², Samir Zakhari³, Radu M Nanau⁴, Sebastian Mueller⁵, Michelle Schneider⁶, Charles Parry⁷, Romina Isip⁴, Helmut K Seitz⁵

Affiliations

¹ In Vitro Drug Safety and Biotechnology, University of Toronto, Toronto, ON, Canada Department of Pharmacology and Toxicology, Faculty of Medicine, University of Toronto, Toronto, ON, Canada manuela.neuman@utoronto.ca.
² Division of Gastroenterology, Sunnybrook Health Sciences Centre, Department of Medicine, Medicine, Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
³ Division of Metabolism and Health Effects, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD, USA.
⁴ In Vitro Drug Safety and Biotechnology, University of Toronto, Toronto, ON, Canada Department of Pharmacology and Toxicology, Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
⁵ Centre of Alcohol Research, University of Heidelberg and Department of Medicine (Gastroenterology and Hepatology), Salem Medical Centre, Heidelberg, Germany.
⁶ Alcohol and Drug Abuse Research Unit, Medical Research Council, Stellenbosch University, Cape Town, South Africa.
⁷ Alcohol and Drug Abuse Research Unit, Medical Research Council, Stellenbosch University, Cape Town, South Africa Department of Psychiatry, Stellenbosch University, Cape Town, South Africa.

PMID: 24816574
PMCID: PMC4072899
DOI: 10.1093/alcalc/agu021

Alcoholic liver disease: a synopsis of the Charles Lieber's Memorial Symposia 2009-2012

Manuela G Neuman et al. Alcohol Alcohol. 2014 Jul-Aug.

. 2014 Jul-Aug;49(4):373-80.

doi: 10.1093/alcalc/agu021. Epub 2014 May 9.

Authors

Manuela G Neuman¹, Lawrence Cohen², Samir Zakhari³, Radu M Nanau⁴, Sebastian Mueller⁵, Michelle Schneider⁶, Charles Parry⁷, Romina Isip⁴, Helmut K Seitz⁵

Affiliations

¹ In Vitro Drug Safety and Biotechnology, University of Toronto, Toronto, ON, Canada Department of Pharmacology and Toxicology, Faculty of Medicine, University of Toronto, Toronto, ON, Canada manuela.neuman@utoronto.ca.
² Division of Gastroenterology, Sunnybrook Health Sciences Centre, Department of Medicine, Medicine, Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
³ Division of Metabolism and Health Effects, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD, USA.
⁴ In Vitro Drug Safety and Biotechnology, University of Toronto, Toronto, ON, Canada Department of Pharmacology and Toxicology, Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
⁵ Centre of Alcohol Research, University of Heidelberg and Department of Medicine (Gastroenterology and Hepatology), Salem Medical Centre, Heidelberg, Germany.
⁶ Alcohol and Drug Abuse Research Unit, Medical Research Council, Stellenbosch University, Cape Town, South Africa.
⁷ Alcohol and Drug Abuse Research Unit, Medical Research Council, Stellenbosch University, Cape Town, South Africa Department of Psychiatry, Stellenbosch University, Cape Town, South Africa.

PMID: 24816574
PMCID: PMC4072899
DOI: 10.1093/alcalc/agu021

Abstract

This paper is based upon the 'Charles Lieber Satellite Symposia' organized by Manuela G. Neuman at each of the 2009-2012 Research Society on Alcoholism (RSA) Annual Meetings. The presentations represent a broad spectrum dealing with alcoholic liver disease (ALD). In addition, a literature search (2008-2013) in the discussed area was performed in order to obtain updated data. The presentations are focused on genetic polymorphisms of ethanol metabolizing enzymes and the role of cytochrome P4502E1 (CYP2E1) in ALD. In addition, alcohol-mediated hepatocarcinogenesis, immune response to alcohol and fibrogenesis in alcoholic hepatitis as well as its co-morbidities with chronic viral hepatitis infections in the presence or absence of human deficiency virus are discussed. Finally, emphasis was led on alcohol and drug interactions as well as liver transplantation for end-stage ALD.

PubMed Disclaimer

Cited by

Patterns of IgA Autoantibody Generation, Inflammatory Responses and Extracellular Matrix Metabolism in Patients with Alcohol Use Disorder.
Niemelä O, Bloigu A, Bloigu R, Nivukoski U, Kultti J, Pohjasniemi H. Niemelä O, et al. Int J Mol Sci. 2023 Aug 23;24(17):13124. doi: 10.3390/ijms241713124. Int J Mol Sci. 2023. PMID: 37685930 Free PMC article.
Molecular, Viral and Clinical Features of Alcohol- and Non-Alcohol-Induced Liver Injury.
Neuman MG, Seitz HK, Teschke R, Malnick S, Johnson-Davis KL, Cohen LB, German A, Hohmann N, Moreira B, Moussa G, Opris M. Neuman MG, et al. Curr Issues Mol Biol. 2022 Mar 16;44(3):1294-1315. doi: 10.3390/cimb44030087. Curr Issues Mol Biol. 2022. PMID: 35723310 Free PMC article. Review.
Hepatoprotective effects of Auricularia cornea var. Li. polysaccharides against the alcoholic liver diseases through different metabolic pathways.
Wang X, Lan Y, Zhu Y, Li S, Liu M, Song X, Zhao H, Liu W, Zhang J, Wang S, Jia L. Wang X, et al. Sci Rep. 2018 May 15;8(1):7574. doi: 10.1038/s41598-018-25830-w. Sci Rep. 2018. PMID: 29765084 Free PMC article.
A cluster randomised controlled trial protocol of an adapted intervention for alcohol use disorders in people living with HIV and AIDS: impact on alcohol use, general functional ability, quality of life and adherence to HAART.
Madhombiro M, Dube-Marimbe B, Dube M, Chibanda D, Zunza M, Rusakaniko S, Stewart D, Seedat S. Madhombiro M, et al. BMC Psychiatry. 2017 Jan 28;17(1):44. doi: 10.1186/s12888-017-1208-3. BMC Psychiatry. 2017. PMID: 28129756 Free PMC article. Clinical Trial.
Alcohol-associated liver disease: A review on its pathophysiology, diagnosis and drug therapy.
Subramaniyan V, Chakravarthi S, Jegasothy R, Seng WY, Fuloria NK, Fuloria S, Hazarika I, Das A. Subramaniyan V, et al. Toxicol Rep. 2021 Feb 19;8:376-385. doi: 10.1016/j.toxrep.2021.02.010. eCollection 2021. Toxicol Rep. 2021. PMID: 33680863 Free PMC article. Review.

See all "Cited by" articles

References

1. Ambade A, Mandrekar P. Oxidative stress and inflammation: essential partners in alcoholic liver disease. Int J Hepatol. 2012;2012:853175. - PMC - PubMed
1. Amir I, Anwar N, Baraona E, et al. Ranitidine increases the bioavailability of imbibed alcohol by accelerating gastric emptying. Life Sci. 1996;58:511–8. - PubMed
1. Bansal S, Liu CP, Sepuri NB, et al. Mitochondria-targeted cytochrome P450 2E1 induces oxidative damage and augments alcohol-mediated oxidative stress. J Biol Chem. 2010;285:24609–19. - PMC - PubMed
1. Bautista AP. Free radicals, chemokines, and cell injury in HIV-1 and SIV infections and alcoholic hepatitis. Free Radic Biol Med. 2001;31:1527–32. - PubMed
1. Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology. 1999;30:1054–8. - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Alcoholic liver disease: a synopsis of the Charles Lieber's Memorial Symposia 2009-2012

Affiliations

Alcoholic liver disease: a synopsis of the Charles Lieber's Memorial Symposia 2009-2012

Authors

Affiliations

Abstract

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Abstract

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Other Literature Sources